Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 126

1.

Comparing biomarkers as principal surrogate endpoints.

Huang Y, Gilbert PB.

Biometrics. 2011 Dec;67(4):1442-51. doi: 10.1111/j.1541-0420.2011.01603.x. Epub 2011 Apr 22.

PMID:
21517791
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Evaluating candidate principal surrogate endpoints.

Gilbert PB, Hudgens MG.

Biometrics. 2008 Dec;64(4):1146-54. doi: 10.1111/j.1541-0420.2008.01014.x. Epub 2008 Mar 24.

PMID:
18363776
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

A shrinkage approach for estimating a treatment effect using intermediate biomarker data in clinical trials.

Li Y, Taylor JM, Little RJ.

Biometrics. 2011 Dec;67(4):1434-41. doi: 10.1111/j.1541-0420.2011.01608.x. Epub 2011 May 31.

PMID:
21627627
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Design and estimation for evaluating principal surrogate markers in vaccine trials.

Huang Y, Gilbert PB, Wolfson J.

Biometrics. 2013 Jun;69(2):301-9. doi: 10.1111/biom.12014. Epub 2013 Feb 14.

PMID:
23409839
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Comparing and combining biomarkers as principle surrogates for time-to-event clinical endpoints.

Gabriel EE, Sachs MC, Gilbert PB.

Stat Med. 2015 Feb 10;34(3):381-95. doi: 10.1002/sim.6349. Epub 2014 Oct 28.

PMID:
25352131
[PubMed - in process]
7.

Chop-lump tests for vaccine trials.

Follmann D, Fay MP, Proschan M.

Biometrics. 2009 Sep;65(3):885-93. doi: 10.1111/j.1541-0420.2008.01131.x. Epub 2009 Feb 5.

PMID:
19210727
[PubMed - indexed for MEDLINE]
8.

Evaluating principal surrogate endpoints with time-to-event data accounting for time-varying treatment efficacy.

Gabriel EE, Gilbert PB.

Biostatistics. 2014 Apr;15(2):251-65. doi: 10.1093/biostatistics/kxt055. Epub 2013 Dec 13.

PMID:
24337534
[PubMed - indexed for MEDLINE]
9.

A simple meta-analytic approach for using a binary surrogate endpoint to predict the effect of intervention on true endpoint.

Baker SG.

Biostatistics. 2006 Jan;7(1):58-70. Epub 2005 Jun 22.

PMID:
15972889
[PubMed - indexed for MEDLINE]
Free Article
10.

Statistical evaluation of biomarkers as surrogate endpoints: a literature review.

Weir CJ, Walley RJ.

Stat Med. 2006 Jan 30;25(2):183-203. Review.

PMID:
16252272
[PubMed - indexed for MEDLINE]
11.

Predicting treatment effect from surrogate endpoints and historical trials: an extrapolation involving probabilities of a binary outcome or survival to a specific time.

Baker SG, Sargent DJ, Buyse M, Burzykowski T.

Biometrics. 2012 Mar;68(1):248-57. doi: 10.1111/j.1541-0420.2011.01646.x. Epub 2011 Aug 13.

PMID:
21838732
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Surrogate endpoints in randomized cardiovascular clinical trials.

Domanski M, Pocock S, Bernaud C, Borer J, Geller N, Revkin J, Zannad F.

Fundam Clin Pharmacol. 2011 Aug;25(4):411-3. doi: 10.1111/j.1472-8206.2010.00865.x. Epub 2010 Aug 4. Review.

PMID:
20698890
[PubMed - indexed for MEDLINE]
13.

Surrogacy assessment using principal stratification when surrogate and outcome measures are multivariate normal.

Conlon AS, Taylor JM, Elliott MR.

Biostatistics. 2014 Apr;15(2):266-83. doi: 10.1093/biostatistics/kxt051. Epub 2013 Nov 26.

PMID:
24285772
[PubMed - indexed for MEDLINE]
14.

Statistical considerations for the next generation of clinical trials.

Wu W, Shi Q, Sargent DJ.

Semin Oncol. 2011 Aug;38(4):598-604. doi: 10.1053/j.seminoncol.2011.05.014. Review.

PMID:
21810519
[PubMed - indexed for MEDLINE]
15.

Odds ratio for 2 × 2 tables: Mantel-Haenszel estimator, profile likelihood, and presence of surrogate responses.

Banerjee B, Biswas A.

J Biopharm Stat. 2014;24(3):649-59. doi: 10.1080/10543406.2014.888568.

PMID:
24697719
[PubMed - indexed for MEDLINE]
16.

Bayesian adaptive trial design for a newly validated surrogate endpoint.

Renfro LA, Carlin BP, Sargent DJ.

Biometrics. 2012 Mar;68(1):258-67. doi: 10.1111/j.1541-0420.2011.01647.x. Epub 2011 Aug 12.

PMID:
21838811
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Semiparametric estimation exploiting covariate independence in two-phase randomized trials.

Dai JY, LeBlanc M, Kooperberg C.

Biometrics. 2009 Mar;65(1):178-87. doi: 10.1111/j.1541-0420.2008.01046.x. Epub 2008 May 13.

PMID:
18479485
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Methodological issues in the use of composite endpoints in clinical trials: examples from the HIV field.

Wittkop L, Smith C, Fox Z, Sabin C, Richert L, Aboulker JP, Phillips A, Chêne G, Babiker A, Thiébaut R; NEAT-WP4.

Clin Trials. 2010 Feb;7(1):19-35. doi: 10.1177/1740774509356117. Review.

PMID:
20156955
[PubMed - indexed for MEDLINE]
19.

An entropy-based nonparametric test for the validation of surrogate endpoints.

Miao X, Wang YC, Gangopadhyay A.

Stat Med. 2012 Jun 30;31(14):1517-30. doi: 10.1002/sim.4500. Epub 2012 Feb 17.

PMID:
22344829
[PubMed - indexed for MEDLINE]
20.

Definitions and validation criteria for biomarkers and surrogate endpoints: development and testing of a quantitative hierarchical levels of evidence schema.

Lassere MN, Johnson KR, Boers M, Tugwell P, Brooks P, Simon L, Strand V, Conaghan PG, Ostergaard M, Maksymowych WP, Landewe R, Bresnihan B, Tak PP, Wakefield R, Mease P, Bingham CO 3rd, Hughes M, Altman D, Buyse M, Galbraith S, Wells G.

J Rheumatol. 2007 Mar;34(3):607-15.

PMID:
17343307
[PubMed - indexed for MEDLINE]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk